Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : pyrazinamide
  • Active substance : isoniazide
  • Topics : Biology (laboratory tests)
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Diagnostic techniques and procedures (1)
    • Plus ...
      • Biology (laboratory tests) (1)
  • Diseases and conditions (1)
  • Plus ...
    • Respiratory tract diseases (1)
    • Plus ...
      • Pulmonary and pleural diseases (1)
    • Infectious diseases (1)
    • Plus ...
      • Bacterial infections (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Health technology assessment (1)
Language
  • Français (1)
Active substance
  • isoniazide (1)
  • pyrazinamide (1)
  • rifampicine (1)

Drugs, devices and medical acts - 1 result

  • Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection

    Health technology assessment - Posted on 29/6/2015
    Download document
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
eNq1WNty2jAQfecrGGbSNzDmTmuTSbg0zCRTGqDt9MUj7AVEjeRIMoF8fWWbDJCYhIjogQGk9dmV9ujsytbleulnV8A4psTOmYViLgvEpR4mMzs3HvXyjdxlK2Mt0ArtmzUKRcdsmLms6yPO7Vw0X5gAIrzw5+62AxIBWK6VyVp0sgBXHNiFAvuFG8TndyiIbLLWimIvuwQxp56dC0IRj2YtLpiMo/VI2T8eIBcsYzuyP7twKvvjlhGBnYAacmC3iMxSQYEoYbohY0BEGwmYUbZJhZ66TqlRrzRLZSUXmN8DpyFzYYDEfMDoCnvgpXtCPgclJ9NHbwhs5YOInKSCGwt3yZXA0QKt7+Ghnx70lZxti7XIF/NmrVSuFatN+V0sKblie1uVTh65CCPJSNWsmwYQQz4T+gKJvAd5Bu4cmPwopmpAmUC+piRh3j6kmyY/DB7eJYOHeeCjTWHBA9WtQgzJaWBSFPQtJFrBiEmZ8uWevcAnoe8bH4x6vBURTRFHGtWmIRFHtGQ8VN2INiUC1sczqiZ/Yr3lIgb+ebBPlKRL/yCc+NhVVTipQSFwMb7vHxc4jdpwjTiMmT5x+I2JRx/554vOfpI1RR/EupkKGjDPdErNRs2sVpXP1F/JqCP1pxsyGoAh5Qjzc1SmT6b0XH2RJE2HeqaoLnbGvRF1kQ9HuiNHUXkkLZ+bOW3E13eokolU0O/dkSpbfobANsP4byo09uxdntV0WYfYS3K+F3nk1P6ClsE3sQziAm+LTQB8elHuCElQQn06kypyUerNgACLanKhu0J+iIS8aHSAj/asOjBEch0xHg2GgCS9E/RELux9aYjHe1ft7sgZjq+dq/ao/6trBxuGnjBBS0kOVQvMKcHS5mB+dNO969quU6vUi1W5HNcxzapZKzfj37VKrVaMrQ9y+XrkDLE84c5RrjeaanLA0rV4LkTAvxrGHPE8j3JTmLKTy+bljh06GPKaJW8x5TQunGH1gjUfYo5qod6den3XRC19ZNJXJ0VaU+iTpPs6ndaq6v5el3nuzWn7/PaGli7DLIQz8pA0AtrKdb/7+R3A7tqkLezBgerqcxNfcWKx09Vrh5M3aoZyVZKJJT0m1eHHdIqPvLo7SkzLSF4btjKWEb0ybGX+A8hPzZk=
rpWqD9JQgVRp0c5w